Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple
A phase 3 trial of Belantamab mafodotin in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Overview
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT04162210 by GlaxoSmithKline, with 325 participants enrolled, started 2020-04-02 and due to reach its primary completion in 2022-09-12. Interventions recorded: Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone). Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialJapan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Belantamab mafodotin, GSK, Multiple myeloma.